Fipexide

Summary

Fipexide (CHEMBL254857) is an approved small molecule (ATC N06BX05); indicated across 1 condition including attention deficit-hyperactivity disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06BX05
• Indications: 1 condition
• Chemistry: 388.8 Da · C20H21ClN2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL254857
Name	Fipexide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3351
ATC	N06BX05
Molecular formula	C20H21ClN2O4
Molecular weight	388.8
InChIKey	BFUJHVVEMMWLHC-UHFFFAOYSA-N

SMILES: C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C(=O)COC4=CC=C(C=C4)Cl

IUPAC name: 1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-2-(4-chlorophenoxy)ethanone

Also known as: Fipexida, Fipexide, NSC-758407, SID11112737, SID49716199, fipexide, FIPEXIDE, FIPEXIDE HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL1377408

Patent coverage: 104 distinct patent families (344 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: Prelamin-A/C, Alpha-2A adrenergic receptor, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor, D(3) dopamine receptor, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 23 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q01827	6.82	AC50	150	nM	CHEMBL_ACT_25197404
CYP2D6	6.7	Potency	199.5	nM	CHEMBL_ACT_4961764
CYP2D6	6.7	AC50	199.5	nM	CHEMBL_ACT_6071559
CYP3A4	6.2	Potency	631	nM	CHEMBL_ACT_4977584
CYP3A4	6.2	Potency	631	nM	CHEMBL_ACT_5046577
CYP3A4	6.2	AC50	631	nM	CHEMBL_ACT_6036163
HIF1A	5.4	Potency	3981	nM	CHEMBL_ACT_4129651
HIF1A	5.4	Potency	3981	nM	CHEMBL_ACT_4518687
CYP2C19	5.3	Potency	5012	nM	CHEMBL_ACT_4021133
CYP2C19	5.3	AC50	5012	nM	CHEMBL_ACT_6035223
CYP1A2	5.3	AC50	5012	nM	CHEMBL_ACT_6042856
CHRM1	5.2	AC50	6270	nM	CHEMBL_ACT_25210585
LMNA	5	Potency	10000	nM	CHEMBL_ACT_3622688

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
attention deficit-hyperactivity disorder	4	MONDO:0007743	EFO:0003888

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).